Healthcare legislation organization Frier Levitt has analyzed FDA enforcement steps versus “research only” peptide sellers. Their summary: the FDA considers an item’s classification dependant on its supposed use, not its disclaimers. When Sites consist of dosage guides, reconstitution Guidelines, or